Drugs / OBX-115
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05470283 | Sep 2022 → Apr 2027 expected | metastatic melanoma | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06060613 | Oct 2023 → Jun 2029 expected | metastatic melanoma, non-small cell lung carcinoma, skin neoplasm | Obsidian Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | OBX-115 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05470283 ↗ |
| Modality | Cell therapy | “OBX-115 + acetazolamide cell therapy” NCT05470283 ↗ |
| Route | Intravenous | “Given by IV” NCT05470283 ↗ |